Ligand partner Spectrum Pharmaceuticals announces NDA for Captisol-enabled™ Melphalan
Ligand announces that its partner Spectrum Pharmaceuticals has submitted a New Drug Application to the FDA for Captisol-enabled™ MelphalanHCl for injection for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. December 26, 2014